NCT01042067

Safer Warfarin Treatment

Safer Warfarin Treatment - the Influence of CYP2C9 Genotyping, Genotyping of Vitamine K Dependent Proteins and Dietary Vitamine K Status on Dosing, Clinical Effect and Adverse Events With Emphasis on the Initial Phase of Treatment

• Status: Suspended
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Oslo University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study is a national multicenter prospective observational study, including 200 patients. The main purpose of this study is to explore in more detail the influence of genetic variability (CYP enzymes and vitamin K dependent proteins) and dietary vitamin K status on warfarin dosing, clinical effect and adverse events with emphasis on the initial phase of treatment. The hypothesis is that genetic variability concerning CYP enzymes and vitamin K dependent proteins predict dosing and adverse events during warfarin treatment. The main aim is to individualize warfarin therapy and establish a treatment algorithm based on genotype and dietary vitamin K status to make the anticoagulation therapy with warfarin more secure.

Conditions

• Atrial Fibrillation
• Venous Thrombosis
• Pulmonary Embolism
• Heart Valve Prosthesis

Interventions

Type	Name	Description
OTHER	Blood specimens (whole blood, serum, plasma)	The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.

Timeline

• Start date: 2010-01-01
• First posted: 2010-01-05
• Last updated: 2011-04-27

Locations

1 site across 1 country: Norway